Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
Status:
Completed
Trial end date:
2016-09-30
Target enrollment:
Participant gender:
Summary
This randomized pilot phase II trial studies and compares prophylactic topical agents in
reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or
breast cancer in situ. The prophylactic topical agents, such as curcumin-based gel or HPR
Plus, may reduce the severity of the radiation-induced dermatitis by minimizing water loss
and inflammation during radiation therapy.